Penetrium Bioscience Inc.
A Hyundai Bioscience-affiliated biotech developing cancer drugs via its Penetrium(TM) platform, alongside CRO services.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2003 and listed on KOSDAQ in 2021, Penetrium Bioscience is a biotech drug developer acquired by Hyundai Bioscience Co., Ltd. in May 2024. It builds its pipeline around Penetrium(TM), a drug-delivery platform, while providing CRO services. Its bio TF team licensed drug-delivery tech from Hyundai Bioscience for breast/lung cancer drugs via a June 26, 2024 deal worth KRW 9.1bn upfront plus milestones.
Products & technology
- Contract Research Organization (CRO) ServiceClinical trial design, operation/management, data management and statistics, pharmacovigilance (PV), regulatory affairs (RA), and quality assurance (QA) for pharmaceutical/biotech clients across Phase 1-3 trials
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2020–2025 (Phase 1 1 · Phase 2a 1 · Phase 2 1)
- Phase 1Penetrium(TM)2025-12-09
1 trial site
- Phase 2aAP-1012021-12-29
1 trial site
- Phase 2CDA-012020-07-08
4 trial sites
R&D and key agreements
Source: DART corporate disclosure유방암 항암제 (약물전달체 기반) · 유방암 · Acquired a portion of exclusive patent license (Patent 10-2378590, held by C&Pharm and We Biotree) from Hyundai Bioscience under a June 26, 2024 Exclusive License Transfer Agreement: KRW 9.1bn upfront, KRW 6.5bn on US Phase 2 success, KRW 5.0bn on US Phase 3 success, KRW 5.0bn on US approval, plus running royalties of 3-10% of net sales by tier
폐암 항암제 (약물전달체 기반) · 폐암(비소세포폐암 등 고형암) · Exclusive license acquired from Hyundai Bioscience under the same June 26, 2024 agreement; prepared mass production of clinical-grade drug in cooperation with Daegu-Gyeongbuk Medical Innovation Foundation (K-Medi Hub) and Yuyoung Pharm
고형암 치료제 (약물전달체 기반, IND 1상) · 고형암(유방암·폐암 등) · IND 1상 승인(2025.12.09, 식품의약품안전처) · Received Investigational New Drug (IND) Phase 1 approval from the Ministry of Food and Drug Safety on December 9, 2025 (source sentence is truncated beyond this point)
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition